IONS

Ionis Pharmaceuticals, Inc.

Halal Rating :
Uncomfortable
Last Price $35.63 Last updated:
Market Cap $6.97b
7D Change -2.68%
1 Year Change -27.45%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Pharmaceutical Preparations
Exchange NASDAQ
Next Earnings Date Oct. 31, 2024

Ionis Pharmaceuticals is a biotechnology company focused on discovering, developing, and commercializing RNA-targeted therapeutics. The company specializes in developing antisense drugs for treating a variety of diseases, including rare genetic disorders, cardiovascular conditions, and neurological diseases.

The company's platform technology, antisense, targets RNA to prevent the production of disease-causing proteins. Ionis has a broad pipeline of drugs in development and several marketed products, including SPINRAZA for spinal muscular atrophy.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $133.81m $305.16m - $22.69m 0.00% 7.44%
June 30, 2024 $225.25m $314.13m - $22.79m 0.00% 7.25%
March 31, 2024 $119.5m $291.12m - $22.11m 0.00% 7.59%

Company Impact

Help us evaluate Ionis Pharmaceuticals, Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Recent News & Updates